Mn Services Vermogensbeheer B.V. Has $7 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Mn Services Vermogensbeheer B.V. lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 94,260 shares of the medical equipment provider’s stock after selling 2,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Hologic were worth $6,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in Hologic in the fourth quarter valued at about $217,529,000. Cetera Investment Advisers boosted its holdings in Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Hologic by 1.3% during the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after purchasing an additional 19,680 shares in the last quarter. Pinebridge Investments L.P. grew its stake in shares of Hologic by 39.8% in the 4th quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after purchasing an additional 113,050 shares during the period. Finally, Clearbridge Investments LLC raised its holdings in shares of Hologic by 51.4% in the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after buying an additional 176,006 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.2 %

HOLX opened at $80.25 on Monday. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The stock has a market capitalization of $18.73 billion, a PE ratio of 40.94, a PEG ratio of 2.64 and a beta of 0.99. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average price of $77.75 and a two-hundred day moving average price of $76.15.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the business posted $0.93 earnings per share. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,280 shares of company stock valued at $1,469,973. Company insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Argus boosted their target price on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Evercore ISI increased their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.